4 days ago
4
David Jagielski, CPA, The Motley Fool
Tue, June 30, 2026 astatine 8:20 AM CDT 4 min read
Although its maturation complaint has been origin for interest for investors successful caller years, Pfizer (NYSE: PFE) is simply a banal that I don't deliberation you should number retired close now. The institution is successful the midst of a transition. It's been acquiring companies that it believes volition presumption it for beardown maturation successful the future.
One accidental that the institution isn't passing up connected is the anti-obesity market. It added Metsera into the fold past year, which could beryllium to beryllium a cardinal acquisition that pays disconnected for the concern successful the agelong haul. Although Pfizer doesn't person an approved GLP-1 value nonaccomplishment cause successful its portfolio conscionable yet, here's wherefore it could extremity up being a large subordinate successful that market.
Missed Nvidia successful 2009? This Rare Signal Is Flashing Again. In 2009, a "Double Down" awesome flashed for a little-known chipmaker called Nvidia. For the archetypal clip successful years, that aforesaid "Total Conviction" awesome is flashing for a institution 1/100th the size of Nvidia. Continue »
The institution aims to beryllium a person successful obesity therapies
Late past year, Pfizer completed the acquisition of Metsera, valuing the endeavor astatine astir $7 billion. By Pfizer's standards, that's not a terribly ample acquisition. In 2023, it acquired oncology institution Seagen for a whopping $43 billion. Both areas of healthcare, however, could beryllium cardinal to the company's semipermanent growth.
GLP-1 whitethorn beryllium much underrated. That's due to the fact that Metsera doesn't person immoderate approved products successful its portfolio today. However, Pfizer is optimistic that down the road, it could beryllium a cardinal subordinate successful the space. CEO Albert Bourla outlined the company's imaginativeness successful the broader obesity abstraction connected the company's net telephone backmost successful May:
We are besides executing with absorption to maximize the worth of our Metsera acquisition. This underpins the strategy intended to presumption Pfizer arsenic a person successful the adjacent procreation of obesity therapies. We mean to beforehand 10 signifier 3 studies this year. We are targeting a archetypal support successful 2028 from a portfolio that includes ultra-long-acting peptides with the potential, if successful, developed and approved for competitory efficacy and tolerability with a differentiated monthly attraction dosing schedule.
Not lone does Pfizer person galore late-stage trials successful the works, but focusing connected monthly dosing could assistance it unafraid an vantage successful the market, and it whitethorn beryllium an charismatic alternate to regular pills and presently approved injectables taken erstwhile per week. While Pfizer inactive has a agelong mode to spell and support isn't guaranteed, the institution has shown that it's superior successful not missing retired connected the lucrative GLP-1 market.
English (CA) · 
English (US) · 
Spanish (MX) ·